Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial
Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respira...
Uloženo v:
| Vydáno v: | Current controlled trials in cardiovascular medicine Ročník 21; číslo 1; s. 1014 - 3 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
10.12.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Objectives
SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure.
Trial design
This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients.
Participants
This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent.
Intervention and comparator
Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer.
The timing and escalation dosing plans for the surfactant are as follows.
Cohort 1:
Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention.
Cohort 2:
Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention.
Cohort 3
: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention.
Cohort 4:
Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention.
The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns.
Comparator: No placebo intervention.
All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician.
Main outcomes
The co-primary outcome is the improvement in oxygenation (PaO
2
/FiO
2
ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO
2
]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers.
Randomisation
After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre.
Blinding (masking)
This is an open-labelled unblinded study.
Numbers to be randomised (sample size)
The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control).
Trial Status
Current protocol version is V2 dated 5
th
of June 2020. The recruitment is currently ongoing and started on the 14
th
of October 2020. The anticipated study completion date is November 2021.
Trial registration
ClinicalTrials.gov:
NCT04362059
(Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number:
2020-001886-35
(Registered 11 May 2020)
Full protocol
The full protocol is attached as an additional file, accessible from the Trials website (Additional file
1
). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file
2
). |
|---|---|
| AbstractList | Abstract Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure. Trial design This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients. Participants This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent. Intervention and comparator Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician. Main outcomes The co-primary outcome is the improvement in oxygenation (PaO2/FiO2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers. Randomisation After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre. Blinding (masking) This is an open-labelled unblinded study. Numbers to be randomised (sample size) The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control). Trial Status Current protocol version is V2 dated 5th of June 2020. The recruitment is currently ongoing and started on the 14th of October 2020. The anticipated study completion date is November 2021. Trial registration ClinicalTrials.gov: NCT04362059 (Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number: 2020-001886-35 (Registered 11 May 2020) Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure. Trial design This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients. Participants This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent. Intervention and comparator Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3 : Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician. Main outcomes The co-primary outcome is the improvement in oxygenation (PaO 2 /FiO 2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO 2 ]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers. Randomisation After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre. Blinding (masking) This is an open-labelled unblinded study. Numbers to be randomised (sample size) The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control). Trial Status Current protocol version is V2 dated 5 th of June 2020. The recruitment is currently ongoing and started on the 14 th of October 2020. The anticipated study completion date is November 2021. Trial registration ClinicalTrials.gov: NCT04362059 (Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number: 2020-001886-35 (Registered 11 May 2020) Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1 ). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2 ). SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure. This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged [greater than or equai to]18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent. The timing and escalation dosing plans for the surfactant are as follows. The co-primary outcome is the improvement in oxygenation (PaO.sub.2/FiO.sub.2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP - PEEP) x PaCO.sub.2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers. Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure. Trial design This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients. Participants This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged [greater than or equai to]18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent. Intervention and comparator Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact[R]), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID[TM] nebulizer, an investigational device based on the Aerogen[R] Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician. Main outcomes The co-primary outcome is the improvement in oxygenation (PaO.sub.2/FiO.sub.2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP - PEEP) x PaCO.sub.2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers. Randomisation After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre. Blinding (masking) This is an open-labelled unblinded study. Numbers to be randomised (sample size) The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control). Trial Status Current protocol version is V2 dated 5.sup.th of June 2020. The recruitment is currently ongoing and started on the 14.sup.th of October 2020. The anticipated study completion date is November 2021. Trial registration ClinicalTrials.gov: NCT04362059 (Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number: 2020-001886-35 (Registered 11 May 2020) Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). Keywords: COVID-19, Randomised controlled trial, protocol, surfactant, Intensive Care, mechanical ventilation, nebulisation ObjectivesSARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure.Trial designThis study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients.ParticipantsThis study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent.Intervention and comparatorIntervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer.The timing and escalation dosing plans for the surfactant are as follows.Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention.Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention.Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention.Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention.The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns.Comparator: No placebo intervention.All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician.Main outcomesThe co-primary outcome is the improvement in oxygenation (PaO2/FiO2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP − PEEP) × PaCO2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers.RandomisationAfter informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre.Blinding (masking)This is an open-labelled unblinded study.Numbers to be randomised (sample size)The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control).Trial StatusCurrent protocol version is V2 dated 5th of June 2020. The recruitment is currently ongoing and started on the 14th of October 2020. The anticipated study completion date is November 2021.Trial registrationClinicalTrials.gov: NCT04362059 (Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number: 2020-001886-35 (Registered 11 May 2020)Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure.OBJECTIVESSARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure.This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients.TRIAL DESIGNThis study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients.This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent.PARTICIPANTSThis study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent.Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician.INTERVENTION AND COMPARATORIntervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician.The co-primary outcome is the improvement in oxygenation (PaO2/FiO2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP - PEEP) × PaCO2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers.MAIN OUTCOMESThe co-primary outcome is the improvement in oxygenation (PaO2/FiO2 ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP - PEEP) × PaCO2]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while ho SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response and tissue damage which may impair surfactant synthesis contributing to alveolar collapse, worsening hypoxia and leading to respiratory failure. The objective of this study is to evaluate the feasibility, safety and efficacy of nebulised surfactant in COVID-19 adult patients requiring mechanical ventilation for respiratory failure. This study is a dose-escalating randomized open-label clinical trial of 20 COVID-19 patients. This study is conducted in two centres: University Hospital Southampton and University College London Hospitals. Eligible participants are aged ≥18, hospitalised with COVID-19 (confirmed by PCR), who require endotracheal intubation and are enrolled within 24 hours of mechanical ventilation. For patients unable to consent, assent is obtained from a personal legal representative (PerLR) or professional legal representative (ProfLR) prior to enrolment. The following are exclusion criteria: imminent expected death within 24 hours; specific contraindications to surfactant administration (e.g. known allergy, pneumothorax, pulmonary hemorrhage); known or suspected pregnancy; stage 4 chronic kidney disease or requiring dialysis (i.e., eGFR < 30); liver failure (Child-Pugh Class C); anticipated transfer to another hospital, which is not a study site, within 72 hours; current or recent (within 1 month) participation in another study that, in the opinion of the investigator, would prevent enrollment for safety reasons; and declined consent or assent. Intervention: The study is based on an investigational drug/device combination product. The surfactant product is Bovactant (Alveofact®), a natural animal derived (bovine) lung surfactant formulated as a lyophilized powder in 108 mg vials and reconstituted to 45 mg/mL in buffer supplied in a prefilled syringe. It is isolated by lung lavage and, by weight, is a mixture of: phospholipid (75% phosphatidylcholine, 13% phosphatidylglycerol, 3% phosphatidylethanolamine, 1% phosphatidylinositol and 1% sphingomyelin), 5% cholesterol, 1% lipid-soluble surfactant-associated proteins (SP-B and SP-C), very low levels of free fatty acid, lyso-phosphatidylcholine, water and 0.3% calcium. The Drug Delivery Device is the AeroFact-COVID™ nebulizer, an investigational device based on the Aerogen® Solo vibrating mesh nebulizer. The timing and escalation dosing plans for the surfactant are as follows. Cohort 1: Three patients will receive 10 vials (1080 mg) each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 2: Three patients will receive 10 vials (1080 mg) of surfactant at dosing times of 0 hours and 8 hours, and 30 vials (3240 mg) at a dosing time of 24 hours. 2 controls with no placebo intervention. Cohort 3: Three patients will receive 10 vials (1080 mg) of surfactant at a dosing time of 0 hours, and 30 vials (3240 mg) at dosing times of 8 hours and 24 hours. 2 controls with no placebo intervention. Cohort 4: Three patients will receive 30 (3240 mg) vials each of surfactant at dosing times of 0 hours, 8 hours and 24 hours. 2 controls. 2 controls with no placebo intervention. The trial steering committee, advised by the data monitoring committee, will review trial progression and dose escalation/maintenance/reduction after each cohort is completed (48-hour primary outcome timepoint reached) based on available feasibility, adverse event, safety and efficacy data. The trial will not be discontinued on the basis of lack of efficacy. The trial may be stopped early on the basis of safety or feasibility concerns. Comparator: No placebo intervention. All participants will receive usual standard of care in accordance with the local policies for mechanically ventilated patients and all other treatments will be left to the discretion of the attending physician. The co-primary outcome is the improvement in oxygenation (PaO /FiO ratio) and pulmonary ventilation (Ventilation Index (VI), where VI = [RR x (PIP - PEEP) × PaCO ]/1000) at 48 hours after study initiation. The secondary outcomes include frequency and severity of adverse events (AEs), Adverse Device Effects (ADEs), Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADEs), change in pulmonary compliance, change in positive end-expiratory pressure (PEEP) requirement of ventilatory support at 24 and 48 hours after study initiation, clinical improvement defined by time to one improvement point on the ordinal scale described in the WHO master protocol (2020) recorded while hospitalised, days of mechanical ventilation, mechanical ventilator free days (VFD) at day 21, length of intensive care unit stay, number of days hospitalised and mortality at day 28. Exploratory end points will include quantification of SARS-CoV-2 viral load from tracheal aspirates using PCR, surfactant dynamics (synthesis and turnover) and function (surface tension reduction) from deep tracheal aspirate samples (DTAS), surfactant phospholipid concentrations in plasma and DTAS, inflammatory markers (cellular and cytokine) in plasma and DTAS, and blood oxidative stress markers. After informed assent, patients fulfilling inclusion criteria will be randomised to 3:2 for the treatment and control arms using an internet-based block randomization service (ALEA tool for clinical trials, FormsVision BV) in combination with electronic data collection. Randomisation will be done by the recruiting centre with a unique subject identifier specific to that centre. This is an open-labelled unblinded study. The total sample size is 20 COVID-19 mechanically ventilated patients (12 intervention; 8 control). Current protocol version is V2 dated 5 of June 2020. The recruitment is currently ongoing and started on the 14 of October 2020. The anticipated study completion date is November 2021. ClinicalTrials.gov: NCT04362059 (Registered 24 April 2020), EUDAMED number: CIV-GB-20-06-033328, EudraCT number: 2020-001886-35 (Registered 11 May 2020) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). |
| ArticleNumber | 1014 |
| Audience | Academic |
| Author | Madsen, Jens Batchelor, James Hussell, Tracy Djukanovic, Ratko Dushianthan, Ahilanandan de la Serna, Jorge Bernardino Brealey, David Matthews, Lewis Feelisch, Martin Berry, Lee Grocott, Michael P. W. Clark, Howard Mogg, Robin Porter, Joanna Postle, Anthony |
| Author_xml | – sequence: 1 givenname: Ahilanandan orcidid: 0000-0002-0165-3359 surname: Dushianthan fullname: Dushianthan, Ahilanandan email: a.dushianthan@soton.ac.uk organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust – sequence: 2 givenname: Howard surname: Clark fullname: Clark, Howard organization: UCLH Biomedical Research Centre Infection and Immunity Theme, EGA Institute for Women’s Health, Faculty of Population Health Sciences, University College London Hospital – sequence: 3 givenname: Jens surname: Madsen fullname: Madsen, Jens organization: EGA Institute for Women’s Health, Faculty of Population Health Sciences, University College London Hospital – sequence: 4 givenname: Robin surname: Mogg fullname: Mogg, Robin organization: Bill and Melinda Gates Medical Research Institute – sequence: 5 givenname: Lewis surname: Matthews fullname: Matthews, Lewis organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust – sequence: 6 givenname: Lee surname: Berry fullname: Berry, Lee organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust – sequence: 7 givenname: Jorge Bernardino surname: de la Serna fullname: de la Serna, Jorge Bernardino organization: National Heart and Lung Institute, Imperial College London, Sir Alexander Fleming Building, NIHR Imperial Biomedical Research Centre – sequence: 8 givenname: James surname: Batchelor fullname: Batchelor, James organization: Clinical Informatics Research Unit (CIRU), University of Southampton, MP852, University Hospital Southampton NHS Foundation Trust – sequence: 9 givenname: David surname: Brealey fullname: Brealey, David organization: Critical Care, University College Hospitals London – sequence: 10 givenname: Tracy surname: Hussell fullname: Hussell, Tracy organization: The Lydia Becker Institute for Immunology and Inflammation, The University of Manchester – sequence: 11 givenname: Joanna surname: Porter fullname: Porter, Joanna organization: UCL Respiratory, University College London and Interstitial Lung Disease Service, University College London NHS Foundation Trust – sequence: 12 givenname: Ratko surname: Djukanovic fullname: Djukanovic, Ratko organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust – sequence: 13 givenname: Martin surname: Feelisch fullname: Feelisch, Martin organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust – sequence: 14 givenname: Anthony surname: Postle fullname: Postle, Anthony organization: Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust – sequence: 15 givenname: Michael P. W. surname: Grocott fullname: Grocott, Michael P. W. organization: Respiratory and Critical Care Theme, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Faculty of Medicine, University of Southampton, University Hospital Southampton NHS Foundation Trust |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33302976$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kslu1TAUhiNURAd4ARYoEpuySPEQ2wkLpOoyXamiC4atdWKf3LpK4mI7lcqj8LT43tvSQajJItbJ_3_HZ9gvdiY_YVG8pOSI0ka-jZQTySvCSEXqtq4r8aTYo6oWlWRU7Nw57xb7MZ4TUvOW18-KXc45Ya2Se8Wfr9jNg4toyziHHkyCKZW9D2U6wzIFhDRijvi-jHiJAcvF6c_lh4q2pZtKsPOQYnmYY9W3bH_zrjwuYwqzSXPYIMcRwtXaDTk-26vyIvjkjR82OaAMMFk_ut9ZbPyUgh-GfEzBwfC8eNrDEPHF9feg-PHp4_fFl-rk9PNycXxSGUlUqniTn44owmvJrCSNsYK0wFqpuEBamwYUNB2qliM0VBrRAbQ9ICOtbFHxg2K55VoP5_oiuPWVtQenNwEfVhpCcmZAjUQC1qStFbG1sBSs7WTddApF0yhhMuv9lnUxdyNak1sXYLgHvf9ncmd65S-1UkwyRTPg8BoQ_K8ZY9KjiwaHASb0c9QspyasEXnwB8XrB9JzP4cpt0qzhjKegYLdqlaQC3BT73Nes4bqY5kxlBBBsuroP6r8WhxdHgz2LsfvGV7dLfRfhTeblQXNVmCCjzFgr41LkNx6yOAGTYleL7HeLrHOS6w3S6xFtrIH1hv6oya-NcUsnlYYbrvxiOsvlioCnQ |
| CitedBy_id | crossref_primary_10_1038_s41598_023_47672_x crossref_primary_10_3389_fimmu_2021_730022 crossref_primary_10_1089_ars_2021_0017 crossref_primary_10_1177_2050313X241236313 crossref_primary_10_33549_physiolres_934763 crossref_primary_10_1007_s00705_022_05545_0 crossref_primary_10_3390_jcm11133577 crossref_primary_10_3390_diagnostics13182964 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-020-04944-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database ProQuest Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 3 |
| ExternalDocumentID | oai_doaj_org_article_e06ae409470d45d1addb648b7e58875c PMC7726271 A650610050 33302976 10_1186_s13063_020_04944_5 |
| Genre | Letter Randomized Controlled Trial Correspondence |
| GeographicLocations | London United Kingdom |
| GeographicLocations_xml | – name: London – name: United Kingdom |
| GrantInformation_xml | – fundername: Bill and Melinda Gates Foundation grantid: INV-016631 funderid: http://dx.doi.org/10.13039/100000865 – fundername: Bill and Melinda Gates Foundation grantid: INV-016631 – fundername: Wellcome Trust grantid: 202865/Z/16/Z – fundername: ; grantid: INV-016631 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-38888b0703462d608cd509a296735e14c8a7a8be793ea816c5baa9fae20969e73 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000600103500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Fri Oct 03 12:44:05 EDT 2025 Tue Nov 04 01:56:53 EST 2025 Thu Sep 04 15:36:59 EDT 2025 Sun Oct 19 01:25:52 EDT 2025 Tue Nov 11 10:19:10 EST 2025 Tue Nov 04 17:44:06 EST 2025 Mon Jul 21 05:58:58 EDT 2025 Sat Nov 29 06:09:45 EST 2025 Tue Nov 18 22:32:05 EST 2025 Sat Sep 06 07:26:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 protocol nebulisation mechanical ventilation Randomised controlled trial Intensive Care surfactant |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-38888b0703462d608cd509a296735e14c8a7a8be793ea816c5baa9fae20969e73 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 content type line 23 ObjectType-Undefined-2 |
| ORCID | 0000-0002-0165-3359 |
| OpenAccessLink | https://link.springer.com/10.1186/s13063-020-04944-5 |
| PMID | 33302976 |
| PQID | 2812326252 |
| PQPubID | 44365 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_e06ae409470d45d1addb648b7e58875c pubmedcentral_primary_oai_pubmedcentral_nih_gov_7726271 proquest_miscellaneous_2470028506 proquest_journals_2812326252 gale_infotracmisc_A650610050 gale_infotracacademiconefile_A650610050 pubmed_primary_33302976 crossref_citationtrail_10_1186_s13063_020_04944_5 crossref_primary_10_1186_s13063_020_04944_5 springer_journals_10_1186_s13063_020_04944_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-12-10 |
| PublicationDateYYYYMMDD | 2020-12-10 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-12-10 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.347911 |
| Snippet | Objectives
SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory... SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory response... Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory... ObjectivesSARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an inflammatory... Abstract Objectives SARS-Cov-2 virus preferentially binds to the Angiotensin Converting Enzyme 2 (ACE2) on alveolar epithelial type II cells, initiating an... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1014 |
| SubjectTerms | Adult Biomedicine Case-Control Studies Coronaviruses COVID-19 COVID-19 - drug therapy COVID-19 - epidemiology COVID-19 - mortality COVID-19 - virology COVID-19 study protocols Drug dosages Feasibility Studies Health Sciences Humans Intensive Care Intensive Care Units - statistics & numerical data Letter London - epidemiology mechanical ventilation Medicine Medicine & Public Health Mortality - trends Nebulizers and vaporizers Nebulizers and Vaporizers - standards Nebulizers and Vaporizers - statistics & numerical data protocol Randomised controlled trial Respiration, Artificial - methods Respiratory Insufficiency - metabolism Respiratory Insufficiency - physiopathology Respiratory Insufficiency - therapy Safety SARS-CoV-2 - genetics Severe acute respiratory syndrome coronavirus 2 Statistics for Life Sciences Surface active agents Surface-Active Agents - administration & dosage Surface-Active Agents - chemistry Surface-Active Agents - therapeutic use surfactant Surfactants Testing Treatment Outcome Ventilation - statistics & numerical data Ventilators |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA6yiPgi3q2uEkFQ0bK9JGnq27i6KOgoeGHfQpqesgNrK9MdH_wp_lq_pO24XVFffBuapJMm5_IdcvIdxh7AhxTOEsWZyFUsaklxKYSN00YLEgnsoQsXhd8Uy6U-PCzfnyr15XPCBnrgYeH2KFGWfBBSJLWQdQp9rJTQVUES-iGdt75APVMwNdhgeNlcTFdktNrrYanDeaVPZcRcYjlzQ4Gt_3ebfMopnU2YPHNqGpzRwWV2aUSRfDHM_go7R-1VduHteE5-jf1YUuUrnVPN-83aX17AAnLgUw68x7fJ5bxrODwjrYnvv_v8-kWclnzV8sDJ0fNHeBZ_wPDHz_iCD0Szm3V4Zbjw5kdbHvhpuad76CBT4T8shwOsuy-r7-g85sIf42eoEHKdfTp4-XH_VTxWYYidSoqTOEeMrCtvGYTKapVoVwNk2KxURS4pFU7bwuqKoOhkdaqcrKwtG0sZoqOSivwG22m7lm4xXkuJViLZUA7gktpGIjqUdSaqnJKmjlg6bYpxI0W5r5RxbEKoopUZNtJgI03YSCMj9mQ75utA0PHX3s_9Xm97enLt8AAiZ0aRM_8SuYg99JJivAnA9JwdbzLgIz2ZllkA9QKVJjKJ2O6sJ1TXzZsnWTOj6ehNpj3KRViaRez-ttmP9OlwLXUb9MHUAAzxnojdHERz-0l5nvuCZGgpZkI7--Z5S7s6CsTiiLRUVqQRezqJ969p_XlNb_-PNb3DLmZePdMMwGCX7UCm6S47776drPr1vaDcPwHz_1By priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFLZgihAX9iVQkJGQAIHVLN7CBbWlFUgwVCxVb5bjvMBIJSmTDgd-Cr-WZ48nJUX0wm0U2xk7-fy99-K3EPIIZYhyFoDlvJCM1wJYybllWaM58BT50IVA4bdqOtUHB-Ve_ODWR7fKFScGoq4757-Rb-TaC3_U1vOXR9-ZrxrlT1djCY3zZM1nKuMTsra1M937MJwjKC35KlRGy40eGTucW3qXRpwTEyNxFLL2_83Nfwin046Tp05Pg1DavfK_y7lKLkd1lG4u8XONnIP2Orn4Lh643yC_plD5kulQ034x91EQ-CYoKroUFUc6eKnTrqEoYmEOdPv9_ptXLCvprKUhuUdPn-A19hGHP31BN-kyY-1iHm4ZIuf8aEtDolvq80Z0CM7wH5aiJK27b7Of2Dk61R_iz1Bq5Cb5vLvzafs1i-UcmJOpOmYFGtu68hTDZV7LVLsatRWbl1IVAjLutFVWV4CMAVZn0onK2rKxkKOZVYIqbpFJ27Vwh9BaCGwFEA0UqAFlthFoZoo651UBaVMnJFu9VeNirnNfcuPQBJtHS7NEgkEkmIAEIxLybBhztMz0cWbvLQ-WoafP0h0udPMvJm56A6m04A1oldZc1BnKkkpyXSkQyO3CJeSxh5rxXILTczaGROAifVYus4nqM6q3qUgTsj7qiRzgxs0rlJnIQb05gVhCHg7NfqT3q2uhW2AfnBpqmHifhNxeYntYUlEUvrIZtqgR6kdrHre0s68hQzmabDJXWUKer_bHybT-_Uzvnr2Ke-RS7ndulqPusE4miFa4Ty64H8ezfv4g7vzfE3Vfmg priority: 102 providerName: ProQuest |
| Title | Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial |
| URI | https://link.springer.com/article/10.1186/s13063-020-04944-5 https://www.ncbi.nlm.nih.gov/pubmed/33302976 https://www.proquest.com/docview/2812326252 https://www.proquest.com/docview/2470028506 https://pubmed.ncbi.nlm.nih.gov/PMC7726271 https://doaj.org/article/e06ae409470d45d1addb648b7e58875c |
| Volume | 21 |
| WOSCitedRecordID | wos000600103500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwELfYhtC-8H4ERmUkJEAQkYdf4Vs3NjGJlaqDqvtkOc5lVBoJalY-8Kfw13J2k0LGQ4IvURKfXds5_-6uvjsT8hhliLQGIExYKkJWcAgzxkwYl4oBixAPrQ8UfitHIzWbZeM2KKzpvN27LUmP1H5ZK_GyQbT1e47OHRHbC_kG2UJxp9xynBxPO_xFCZuyLjzmt_V6Ishn6v8Vj38SSBedJS_smHpBdHDt_4ZwnVxtFU86XHHKDXIJqpvkylG7tX6LfBtB7g5Hh4I2y4WLd8A5p6jSUlQR6dofndYlRWEKC6B776aHr8M4o_OK-jQeDX2K78JjrP7sFR3SVW7a5cI36WPkXG1DfUpb6jJE1MiG_jcMRZlZ1J_mX5G4dZ8_w1t_qMht8uFg__3em7A9uCG0IpLnYYpmtcodmDCRFCJStsAPZZJMyJRDzKwy0qgcEBvAqFhYnhuTlQYSNKgykOkdslnVFdwjtOAcSwF4CSnqOrEpORqUvEhYnkJUFgGJu2-pbZvV3B2ucaa9daOEXk26xknXftI1D8jzdZ3Pq5wef6XedSyypnT5uP2LenGq2-WtIRIGnKkso4LxIkapkQumcgkcUZzbgDxxDKYdamD3rGmDH3CQLv-WHqKijIpsxKOA7PQocbXbfnHHorpFm0YnyinGaMkmAXm0LnY1nQddBfUSabBrqEtiOwG5u-Lo9ZDSNHVnmGGJ7PF6b8z9kmr-0eciR-NMJDIOyIuO4390689zev_fyB-Q7cQtmjhBrWGHbCL3wkNy2X45nzeLAdmQk6m7zqS_qgHZ2t0fjScD_wcLPo0Pj8YnA48S3wHuIFt9 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKQcCFfQkUMBIIEERNHDtOkBAaWqqOOh0qKFVvxnFeYKSSlEkHBD-FH8Fv5NmTpKSI3nrgNoqXsZ3vbfFbCHmAMkQaDeAzHsU-zwX4KefaD4uEAw-QHxoXKDyS43Gyu5tuLZBfbSyMdatseaJj1Hll7DfyZZZY4Y_aOnu5_8W3VaPs7WpbQmMOiw34_g1NtvrFcBXf70PG1l5vr6z7TVUB38SBPPAjtPmSzCKdxyyPg8TkKDQ1S2MZCQi5SbTUSQYIXNBJGBuRaZ0WGhhq-ynICOc9RU4jHw-tC5l8u9PdWsgk5m1gThIv1ygf3C2pdaDEE_BFT_i5GgF_S4I_ROFRN80jd7VOBK5d_N8O7xK50CjbdDCnjstkAcor5Oxm405wlfwcQ2YLwkNO69nUxnggziiq8RTVYtr54NOqoKhAwBToypud4aofpnRSUpe6pKaP8Zn_Doc_eU4HdJ6PdzZ1U7q4QDtaU5fGl9qsGBWSnvsPTVFPyKvPkx_YuQkZ2MOfrpDKNfL-RE7mOlksqxJuEpoLga0AooAI9btQFwKNaJEznkUQFLlHwhZFyjSZ3G1BkT3lLLokVnPkKUSecshTwiNPuzH78zwmx_Z-ZcHZ9bQ5yN2DavpRNSxNQRBrsJ8HZJBzkYcoKbOYJ5kEgZJLGI88stBWllPi8oxuAj5wkzbnmBqgcYDKeyACjyz1eiKHM_3mFtWq4bC1OoS0R-53zXak9RosoZphH1wa6s84j0duzGmp21IURbZuG7bIHpX19txvKSefXP51NEhjJkOPPGvp8XBZ_z7TW8fv4h45t769OVKj4XjjNjnPLNcIGWpJS2QRkQt3yBnz9WBST-86nkPJh5Om09-Jv7mn |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKiyou7EuggJFAgCCaxLGdBAmhocOIUdthJBaVk3GSFxipJGXSAcFP4afw63h2lpIieuuB2yhexna-t8VvIeQuypAw1QAu44F0eSbAjTnXrp9HHLiH_DC1gcLb4XQa7e7GsxXyq42FMW6VLU-0jDorU_ONfMAiI_xRW2eDvHGLmI3Gz_a_uKaClLlpbctp1BDZgu_f0Hyrnk5G-K7vMTZ-8WbzpdtUGHBT6YUHboD2X5QY1HPJMulFaYYCVLNYhoEAn6eRDnWUAIIYdOTLVCRax7kGhpp_DGGA854ia6iSc6SxtdlkZ_a-u8MII8nbMJ1IDiqUFvbO1LhT4nm4oicKbcWAv-XCH4LxqNPmkZtbKxDH5_7nozxPzjZqOB3WdHOBrEBxkazvNI4Gl8jPKSSmVDxktFouTPQHIpCigk9RYaaddz4tc4qqBSyAbr56Nxm5fkznBbVJTSr6AJ-5r3H4wyd0SOtMvcuFndJGDJrRmtoEv9TkyyiRKO1_aIoaRFZ-nv_Azk0wwR7-tCVWLpO3J3IyV8hqURZwjdBMCGwFEDkEqPn5OhdoXouM8SQAL88c4reIUmmT492UGtlT1taLpKpRqBCFyqJQCYc86sbs1xlOju393AC162myk9sH5eKjapidAk9qMB8OQi_jIvNRhiaSR0kIAmWaSB1y38BcGR6Ky0t1EwqCmzTZyNQQzQZU6z3hOWSj1xN5X9pvbhGuGt5bqUN4O-RO12xGGn_CAsol9sGloWaN8zjkak1X3ZaCIDAV3bAl7FFcb8_9lmL-yWZmR1NVstB3yOOWNg-X9e8zvX78Lm6TdSRPtT2Zbt0gZ5hhID5D9WmDrCJw4SY5nX49mFeLWw0DouTDSRPqbwYKw8o |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nebulised+surfactant+for+the+treatment+of+severe+COVID-19+in+adults+%28COV-Surf%29%3A+A+structured+summary+of+a+study+protocol+for+a+randomized+controlled+trial&rft.jtitle=Trials&rft.au=Dushianthan%2C+Ahilanandan&rft.au=Clark%2C+Howard&rft.au=Madsen%2C+Jens&rft.au=Mogg%2C+Robin&rft.date=2020-12-10&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft.spage=1014&rft_id=info:doi/10.1186%2Fs13063-020-04944-5&rft_id=info%3Apmid%2F33302976&rft.externalDocID=33302976 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |